drugset / Trial / NCT00311753

Efficacy and Safety of Low-molecular Weight Heparin for Thromboprophylaxis in Acutely Ill Medical Patients

NCT00311753

Phase 3 Completed 342 enrolled Novartis Pharmaceuticals
RandomizedParallel-groupOpen-labelPrevention

Summary

Acutely ill immobilized patients are at a high risk for thromboembolic events including deep venous thrombosis or pulmonary embolism. Unfractionated heparin (UFH) and low molecular weight heparins (LMWH) are thought to be effective in preventing thromboembolic events. This study is designed to provide efficacy and safety data for thromboprophylaxis with the LMWH certoparin in comparison to thromboprophylaxis with UFH in acutely ill non-surgical patients.

Timeline

Start
2006-02
Primary completion
2007-12
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject Certoparin Other / unclassified 3000 iu
Comparator Heparin Other / unclassified 7500 iu